mibavademab

Phase 3Monoclonal antibody

Regeneron

mibavademab is one of 44 small molecule programs targeting Generalized Lipodystrophy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Generalized LipodystrophyActive, not recruiting

AmenorrheaActive, not recruiting

ObesityActive, not recruiting

Generalized LipodystrophyPhase 3

Active, not recruiting

AmenorrheaPhase 2

Active, not recruiting

ObesityPhase 3

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

mibavademab

Regeneron

Phase 3

2 2

Amidate

Adenocard

Colcrys

Alnylam Pharmaceuticals

Activella

Calciferol

Alnylam Pharmaceuticals

Cetrotide

2 8

Advil

KKenvue Brands

Preclinical

1 9

Prometrium

Ferring

Preclinical

1 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Generalized Lipodystrophy

NCT06548100

Q4 2027

Phase 2Recruiting

Amenorrhea

NCT07235917

Q2 2028

Phase 3Recruiting

Obesity

NCT07220772

Q3 2028

Phase 3Recruiting

Generalized Lipodystrophy

NCT07220785

Clinical

Trials by Indication[1]

Generalized Lipodystrophy2 trials

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

Active, not recruiting· Regeneron logo

Regeneron·Phase 3·NCT06548100·9 enrolled

A Two-Part, Randomized, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Mibavademab in Patients With Generalized Lipodystrophy (LAGO)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07220785·28 enrolled

Obesity2 trials

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07220772·4 enrolled

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT06373146·392 enrolled

Amenorrhea1 trial

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07235917·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for mibavademab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mibavademab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mibavademab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Regeneron

mibavademab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Generalized Lipodystrophy2 trials

Obesity2 trials

Amenorrhea1 trial

References

Drug Info

Quick Facts

Related News